Justin J. McAnear
Justin J. McAnear's purchase track record
Justin J. McAnear has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/13/2022 | TXG | $6K | +1.3% | -13.3% | -0.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
10x Genomics Partners With Fred Hutchinson Cancer Center. 10x Genomics announced a new collaboration with the Fred Hutchinson Cancer Center to apply single-cell and spatial technologies to solid tumors and blood cancers. This partnership aims to advance research in hematologic malignancies. Separately, Barclays raised its price target for the stock to $110, reflecting continued analyst interest in the company's growth potential.
Transaction History
| ALMR | ▲ Buy | Grant | 37,220 | $0 | 4/20/2026 | View on chart |
| TXG | ▼ Sell | Open Market | 2,961 | $67K | 8/22/2024 | View on chart |
| TXG | ▼ Sell | Open Market | 2,936 | $71K | 5/22/2024 | View on chart |
| TXG | ▲ Buy | Grant | 53,312 | $0 | 3/21/2024 | View on chart |
| TXG | ▼ Sell | Open Market | 1,865 | $86K | 2/22/2024 | View on chart |
| TXG | ▼ Sell | Open Market | 1,679 | $73K | 11/22/2023 | View on chart |
| TXG | ▼ Sell | Open Market | 1,678 | $77K | 8/22/2023 | View on chart |
| TXG | ▼ Sell | Open Market | 194 | $11K | 5/23/2023 | View on chart |
| TXG | ▼ Sell | Open Market | 465 | $26K | 5/23/2023 | View on chart |
| TXG | ▼ Sell | Open Market | 565 | $31K | 5/23/2023 | View on chart |
| TXG | ▼ Sell | Open Market | 441 | $24K | 5/23/2023 | View on chart |
| TXG | ▲ Buy | Grant | 25,991 | $0 | 3/21/2023 | View on chart |
| TXG | ▼ Sell | Open Market | 1,245 | $59K | 2/22/2023 | View on chart |
| TXG | ▼ Sell | Open Market | 652 | $22K | 11/22/2022 | View on chart |
| TXG | ▼ Sell | Open Market | 686 | $23K | 11/22/2022 | View on chart |
| TXG | ▼ Sell | Open Market | 288 | $10K | 11/22/2022 | View on chart |
| TXG | ▲ Buy | Grant | 20,297 | $0 | 9/14/2022 | View on chart |
| TXG | ▼ Sell | Open Market | 987 | $35K | 8/23/2022 | View on chart |
| TXG | ▼ Sell | Open Market | 967 | $47K | 5/23/2022 | View on chart |
| TXG | ▲ Buy | Open Market | 158 | $6K | 5/13/2022 | View on chart |
| TXG | ▲ Buy | Grant | 21,357 | $0 | 3/22/2022 | View on chart |
| TXG | ▼ Sell | Open Market | 288 | $23K | 2/22/2022 | View on chart |
| TXG | ▲ Buy | Option Exercise | 10,000 | $50K | 1/3/2022 | View on chart |
| TXG | ▼ Sell | Open Market | 1,334 | $196K | 1/3/2022 | View on chart |
| TXG | ▼ Sell | Open Market | 3,583 | $520K | 1/3/2022 | View on chart |
| TXG | ▼ Sell | Open Market | 4,083 | $596K | 1/3/2022 | View on chart |
| TXG | ▼ Sell | Open Market | 500 | $74K | 1/3/2022 | View on chart |
| TXG | ▼ Sell | Open Market | 500 | $75K | 1/3/2022 | View on chart |
| TXG | ▼ Sell | Open Market | 1,536 | $225K | 12/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 2,700 | $399K | 12/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 600 | $90K | 12/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 500 | $75K | 12/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 300 | $45K | 12/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 300 | $46K | 12/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 200 | $31K | 12/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 100 | $16K | 12/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 1,302 | $193K | 12/1/2021 | View on chart |
| TXG | ▲ Buy | Option Exercise | 10,000 | $50K | 12/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 2,462 | $358K | 12/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 281 | $42K | 11/22/2021 | View on chart |
| TXG | ▲ Buy | Option Exercise | 10,000 | $50K | 11/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 300 | $48K | 11/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 500 | $81K | 11/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 4,667 | $762K | 11/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 4,333 | $711K | 11/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 200 | $33K | 11/1/2021 | View on chart |
| TXG | ▲ Buy | Option Exercise | 10,000 | $50K | 10/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 2,500 | $357K | 10/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 1,200 | $173K | 10/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 634 | $90K | 10/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 5,666 | $815K | 10/1/2021 | View on chart |
| TXG | ▲ Buy | Option Exercise | 10,000 | $50K | 9/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 1,139 | $200K | 9/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 2,200 | $389K | 9/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 1,540 | $275K | 9/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 374 | $65K | 9/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 4,747 | $844K | 9/1/2021 | View on chart |
| TXG | ▼ Sell | Open Market | 270 | $44K | 8/23/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Alamar Biosciences Sets Q3 2026 Earnings Release Date
Alamar Biosciences will report its third‑quarter 2026 financial results on November 3, 2026. The company’s latest article highlights a growing focus on its consumables business, suggesting a potential shift in revenue streams. Investors may watch the earnings release for updates on this strategy.
Alamar Biosciences Sets Q3 2026 Earnings Release Date. Alamar Biosciences will report its third‑quarter 2026 financial results on November 3, 2026. The company’s latest article highlights a growing focus on its consumables business, suggesting a potential shift in revenue streams. Investors may watch the earnings release for updates on this strategy.